FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1832-1833 June 6, 2002 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Between 1978, when tamoxifen was first marketed in the United States, and April 2001, there were 43 cases, reported either to the Food and Drug Administration (FDA) or in the medical literature,¹ of uterine sarcoma that developed in women in the United States who had been receiving tamoxifen (Nolvadex, AstraZeneca) for breast cancer; these included one woman with ductal carcinoma in situ and one with stage I breast cancer. In addition, uterine sarcoma was reported to have developed in 116 women in other countries after they had taken tamoxifen for breast cancer. Primary histologic findings were consistent . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Buzdar, A. U., Cuzick, J. (2006). Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data. Clin. Cancer Res. 12: 1037s-1048s [Abstract] [Full Text]  
• Wysowski, D. K., Swartz, L. (2005). Adverse Drug Event Surveillance and Drug Withdrawals in the United States, 1969-2002: The Importance of Reporting Suspected Reactions. Arch Intern Med 165: 1363-1369 [Abstract] [Full Text]  
• Swerdlow, A. J., Jones, M. E., For the British Tamoxifen Second Cancer Study Grou, (2005). Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study. JNCI J Natl Cancer Inst 97: 375-384 [Abstract] [Full Text]  
• Tobias, J. S. (2004). Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Ann Oncol 15: 1738-1747 [Abstract] [Full Text]  
• Curtis, R. E., Freedman, D. M., Sherman, M. E., Fraumeni, J. F. Jr. (2004). Risk of Malignant Mixed Mullerian Tumors After Tamoxifen Therapy for Breast Cancer. JNCI J Natl Cancer Inst 96: 70-74 [Abstract] [Full Text]  
• Peshkin, B. N., Isaacs, C., Finch, C., Kent, S., Schwartz, M. D. (2003). Tamoxifen As Chemoprevention in BRCA1 and BRCA2 Mutation Carriers With Breast Cancer: A Pilot Survey of Physicians. JCO 21: 4322-4328 [Abstract] [Full Text]  
• Ford, L. G., Minasian, L. M., McCaskill-Stevens, W., Pisano, E. D., Sullivan, D., Smith, R. A. (2003). Prevention and Early Detection Clinical Trials: Opportunities for Primary Care Providers and Their Patients. CA Cancer J Clin 53: 82-101 [Abstract] [Full Text]